Avery Therapeutics Overview

  • Founded
  • 2015
  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Latest Deal Amount
  • $30K
Latest Deal Amount
  • Investors
  • 3

Avery Therapeutics General Information


Developer of advanced tissue-engineered therapeutics designed to treat diseases and injuries of human muscles. The company's advanced tissue engineered heart graft contains multiple cell types that is implanted on the surface of a damaged heart, enabling patients to improve blood flow of previously damaged tissues and improve heart functions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 1501 North Campbell Avenue
  • Sarver Heart Center, Room 6154
  • Tucson, AZ 85724
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Avery Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator 23-Feb-2018 $30K 00000 Completed Startup
2. Convertible Debt 01-Jun-2017 00000 00000 Completed Startup
1. Grant 22-Aug-2015 $484K Completed Startup
To view Avery Therapeutics’s complete valuation and funding history, request access »

Avery Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Jordan Lancaster Ph.D Co-Founder & Chief Executive Officer
Jen Koevary Ph.D Chief Operating Officer
Steven Goldman MD Co-Founder & Chief Medical Officer
To view Avery Therapeutics’s complete executive team members history, request access »

Avery Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Flinn Foundation Accelerator/Incubator 000 0000 000000 0
Desert Angels Angel Group Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view Avery Therapeutics’s complete investors history, request access »